开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 02-06 16:08:02

2.630

+0.030

+1.15%

最高2.660	最低2.520	成交量91.85万
今开2.600	昨收2.600	日振幅5.38%
总市值13.12亿	流通市值13.12亿	总股本4.99亿
成交额239.19万	换手率0.18%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.63,"timestamp":1770365282644,"preClose":2.6,"halted":0,"volume":918500,"delay":0,"changeRate":0.011538461538461463,"floatShares":499000000,"shares":499000000,"eps":-0.360537,"marketStatus":"休市中","change":0.03,"latestTime":"02-06 16:08:02","open":2.6,"high":2.66,"low":2.52,"amount":2391915,"amplitude":0.053846,"askPrice":2.65,"askSize":37000,"bidPrice":2.63,"bidSize":130500,"shortable":0,"etf":0,"ttmEps":-0.367,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.6,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0.43017047585379214,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939/tweets","defaultTab":"tweets","newsList":[{"id":"2609736518","title":"六大领域齐发力\n青海中（藏）医药为健康青海添动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2609736518","media":"西海都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609736518?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:13","pubTimestamp":1770397980,"startTime":"0","endTime":"0","summary":"青海省中医院、青海省藏医院与西宁14家社区卫生服务中心签约，推动优质资源下沉。此外，青海还广泛开展中（藏）医药文化传播活动，举办“从二十四节气走进青海传统中（藏）医药”系列活动，通过文化进校园、体验日等多种形式，增进群众对中（藏）医药文化的了解和认同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-07/doc-inhkxipv4703989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159938","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2609947255","title":"华昊中天医药-B(02563)：中国证监会就公司股份全流通发出备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609947255","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609947255?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:46","pubTimestamp":1770389214,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)发布公告，本公司已接获中国证监会就申请于2026年2月5日发出的备案通知书。根据备案通知书，本公司已就实施H股全流通完成向中国证监会备案。备案通知书将自其发出日期起12个月内有效。本公司将向联交所申请转换及上市。于本公告日期，转换及上市的实施计划详情尚未最终确定。本公司将根据上市规则及适用法律的规定于适当时候就转换及上市的进展及详情作出进一步公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1574","02563","BK1515","159938","BK1161"],"gpt_icon":0},{"id":"2609241593","title":"华润医药(03320)：天士力医药2025年度归母净利润11.05亿元，同比增长15.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609241593","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609241593?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:40","pubTimestamp":1770381648,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布天士力医药截至2025年12月31日止年度的未经审核初步财务资料，天士力医药实现总营业收入人民币82.36亿元，同比下降3.08%，实现归属于上市公司股东的净利润人民币11.05亿元，同比增长15.68%。从变动幅度上看，公司营业收入同比下降的主要原因是医药商业收入(主要为连锁药店业务)受“门诊统筹”等行业性政策的影响同比减少14.24%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600535","09939","159938","03320"],"gpt_icon":0},{"id":"2609151371","title":"国泰海通｜医药：美国医药调研及JPM大会后反馈","url":"https://stock-news.laohu8.com/highlight/detail?id=2609151371","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609151371?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:14","pubTimestamp":1770380040,"startTime":"0","endTime":"0","summary":"报告来源以上内容节选自国泰海通证券已发布的证券研究报告。报告名称：美国医药调研及JPM大会后反馈；报告日期：2026.02.05 报告作者：余文心（分析师），登记编号：S0880525040111余克清（分析师），登记编号：S0880525120002陈铭（分析师），登记编号：S0880525100004廖博闻，登记编号：S0880125042239重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650536506&idx=2&sn=1a0d94c26ff1edf4d64d1d36857bd4e0&chksm=897cc698c755bf72a56fe066a10d21f92d5ff1df83c0b6d307b4f2d677cdb4bf2f21a806e034&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0238689110.USD","02611","159938","LU1496350171.SGD","LU0640476718.USD","LU0106261372.USD","BK0188","LU2552382215.SGD","LU1670628061.USD","LU0211328371.USD","LU0251132253.USD","LU0256863811.USD","BK0183","IE00BDCRKT87.USD","LU2237443895.HKD","LU2237443622.USD","LU2357305700.SGD","LU2430703095.HKD","09939","LU0310799852.SGD","BK4581","LU0943347566.SGD","LU0882574139.USD","LU2023250504.SGD","LU0942090050.USD","LU0820561909.HKD","LU2237443382.USD","601211","IE000M9KFDE8.USD","LU1261432733.SGD","LU0234572021.USD","LU0320765489.SGD","LU0320765646.SGD","LU1551013342.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","IE00BJLML261.HKD","BK0276","LU2417539215.USD","LU0006306889.USD","LU0211327993.USD","LU0868494708.USD","IE0034235303.USD","LU0964807845.USD","IE00BN8TJ469.HKD","LU1720051017.SGD","LU2746668461.USD","LU2592432038.USD","IE00B775SV38.USD","BK4588"],"gpt_icon":0},{"id":"2609856571","title":"同源康医药-B(02410)：甲磺酸艾多替尼片（TY-9591片）的新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609856571","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609856571?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:02","pubTimestamp":1770368535,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司在研1类新药甲磺酸艾多替尼片的新药上市申请被国家药品监督管理局药品审评中心受理。甲磺酸艾多替尼片作为奥希替尼的氘代化合物，无论是从化学结构、药理作用、临床有效性和安全性、以及耐药机制分析，甲磺酸艾多替尼片都显示出更明显的临床价值和优势，对疾病的预后有明显改善作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02410","TY","09939","BK1515","159938"],"gpt_icon":0},{"id":"2609683705","title":"亿帆医药：未来将更加聚焦现有合成生物及医药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2609683705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609683705?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:57","pubTimestamp":1770364626,"startTime":"0","endTime":"0","summary":"证券之星消息，亿帆医药(002019)02月06日在投资者关系平台上答复投资者关心的问题。投资者提问：海南希睿达在2023年之前是公司的子公司，但后来股权转让不再是了。请问公司是基于什么考虑在2023年底转让了海南希睿达？亿帆医药回复：公司始终坚持“创新与国际化”中长期规划，未来将更加聚焦现有合成生物及医药领域。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600023397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002019","BK1161","BK1574","09939","BK0197","BK0185","BK1515","BK0077","159938","BK0191","BK0070","BK0239"],"gpt_icon":0},{"id":"2609786559","title":"港股异动 | 同源康医药-B(02410)午后涨近5% 甲磺酸艾多替尼片获纳入优先审评品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2609786559","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609786559?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:19","pubTimestamp":1770358758,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B(02410)午后涨近5%，截至发稿，涨3.65%，报13.06港元，成交额2890.62万港元。消息面上，同源康医药此前公布，公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心(CDE)纳入优先审评品种名单。据悉，该药物拟用于治疗具有表皮生长因子受体(EGFR)外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。此次被纳入优先评审，标志着甲磺酸艾多替尼片的审评进程将全面提速，有望更早上市，为中国患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","09939","BK1574","02410","BK4588","VXUS","BK1515","159938","VT","BK1161"],"gpt_icon":0},{"id":"2609327740","title":"交银国际：预计医药板块今年持续稳中向好 建议寻找被低估医药股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609327740","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609327740?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:54","pubTimestamp":1770281655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，恒生医疗保健指数本周累跌3.3%，表现跑输大市，去年第四季至今内资通过港股通持有医药股的比例亦出现轻微下降，外资持仓则有所提升，部分加仓创新药械及受惠于需求复苏的龙头CXO企业。在今年医药业务拓展中，交银国际建议关注小核酸、长效制剂、invivo CAR-T、新一代ADC/XDC等差异化平台，以及自免、代谢、CNS等疾病领域，认为该板块稳中向好的趋势将于今年延续，但仍有可能出现短期波动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","SG9999014674.SGD","02595","02268","00013","BK1588","BK1583","BK1587","LU2488822045.USD","BK1593","BK1161","BK1574","BK1141","BK1191","09939","03329","BK1515","01530","HK0000165453.HKD","BK1147"],"gpt_icon":0},{"id":"2609322232","title":"2月5日常山药业跌5.20%，医药LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609322232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609322232?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:40","pubTimestamp":1770280828,"startTime":"0","endTime":"0","summary":"证券之星消息，2月5日常山药业跌5.20%创60日新低，收盘报46.1元，换手率2.51%，成交量23.04万手，成交额10.69亿元。融资融券方面近5日融资净流出1.59亿，融资余额减少；融券净流入0.0，融券余额增加。重仓常山药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的医药LOF。医药LOF目前规模为6.54亿元，最新净值0.5716，较上一交易日上涨1.1%，近一年上涨10.95%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500026256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","159938","BK1161","BK0172","BK1515","BK1574","09939","300255"],"gpt_icon":0},{"id":"2609326698","title":"特色原料药——化工涨价潮中的\"医药入口\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2609326698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609326698?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:03","pubTimestamp":1770275019,"startTime":"0","endTime":"0","summary":"特色原料药绝非普通化工品。特色原料药的\"入口\"价值在此体现为独特的双向传导机制。公司聚焦肝病、呼吸系统、神经系统等特色原料药，避开大宗API的红海竞争，单品种毛利率长期维持在50%以上。这种\"进可攻退可守\"的特性，正是特色原料药作为\"医药入口\"的核心投资价值。在化工涨价潮涌动的当下，这一\"医药入口\"的战略价值或正被重新发现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026020500018903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2609445349","title":"医药韧性凸显！中药龙头领涨，场内唯一药ETF逆市飘红！规模最大医疗ETF（512170）吸金26亿后延续高频溢价","url":"https://stock-news.laohu8.com/highlight/detail?id=2609445349","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609445349?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:22","pubTimestamp":1770261720,"startTime":"0","endTime":"0","summary":"2月5日早盘，A股低开低走，大幅调整，医药板块逆市飘红彰显韧性。　　医疗板块大权重龙头坚挺，药明康德涨超1%，医美龙头爱美客大涨超4%，爱尔眼科涨超2%，全市场规模最大医疗ETF水面附近盘整，场内频现溢价。此前资金连续13日低吸，累计净申购26.88亿元。场内唯一药ETF溢价飘红，此前9日获超2400万元增仓。ETF标的指数权重数据截至2026.1.31。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-05/doc-inhktspm9056038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["512170","159938","562050","BK1161","BK1574","159828","09939","BK1515"],"gpt_icon":0},{"id":"2608986043","title":"每日卖空追踪 | 同源康医药-B 02月04日卖空量成交500股，卖空比例为0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608986043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608986043?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:30","pubTimestamp":1770193830,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间02月04日，涨0.08%，卖空量成交500股，较上一交易日减少80%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163637a6d20465&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204163637a6d20465&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1515","09939","02410"],"gpt_icon":0},{"id":"2609969413","title":"劲方医药-B02月04日获主力加仓125.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609969413","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609969413?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:15","pubTimestamp":1770192941,"startTime":"0","endTime":"0","summary":"02月04日, 劲方医药-B股价涨7.33%，报收32.78元，成交金额3446.5万元，换手率0.32%，振幅8.97%，量比1.83。劲方医药-B今日主力资金净流入125.0万元，上一交易日主力净流入93.2万元。该股近5个交易日上涨7.06%，主力资金累计净流入7.0万元；近20日主力资金累计净流入1799.0万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204161912a6d1f143&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204161912a6d1f143&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","02595","BK1161","09939"],"gpt_icon":0},{"id":"2609397127","title":"开拓药业-B02月04日主力净流入67万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2609397127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609397127?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:15","pubTimestamp":1770192917,"startTime":"0","endTime":"0","summary":"02月04日，开拓药业-B股价收平报2.70元，成交金额388.2万元，换手率0.29%，振幅2.96%，量比0.35。开拓药业-B今日主力资金净流入67万元，上一交易日主力净流出0万元。该股近5个交易日下跌7.22%，主力资金累计净流入21.1万元；近20日主力资金累计净流入1452.9万元，其中净流入天数为10日。该股主力净额占比0.05%，港股市场排名158/2711。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204161557a47af82e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204161557a47af82e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2608333345","title":"OpenAI掘金医药新战场：拟推“投资+版税”模式，剑指AI生物科学前沿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608333345","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608333345?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:22","pubTimestamp":1770171726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，OpenAI首席执行官Sam Altman表示，该公司可能会考虑投资或补贴那些大量使用其人工智能技术来发现新药或疗法的公司，并可能收取相应的专利费。思科系统公司人工智能大会上，Altman周二表示，人工智能开发商可以选择与制药公司合作，共同承担使用其人工智能模型的成本，然后从该公司取得的发现中“获得一些版税” 。但Altman表示，OpenAI不会向仅仅通过应用程序编程接口使用其模型的客户收取费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","159938","09939"],"gpt_icon":0},{"id":"2608433128","title":"好医生云医疗集团与京东健康达成战略合作，共赴医药数字化升级新未来！","url":"https://stock-news.laohu8.com/highlight/detail?id=2608433128","media":"数字化企业网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608433128?lang=zh_cn&edition=full","pubTime":"2026-02-04 10:06","pubTimestamp":1770170770,"startTime":"0","endTime":"0","summary":"1月29日，好医生云医疗集团与京东健康正式签署战略合作协议。此次与京东健康达成战略合作，标志着好医生云医疗集团“数智化赋能基层医疗”战略迈出关键一步。好医生云医疗集团总经理苏亚洲在签约现场表示：“通过与京东健康的合作，我们将进一步发挥在基层医疗资源整合与数字化赋能方面的优势，让优质基层医疗资源更智能、更精准地触达千家万户。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204100759a479b383&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204100759a479b383&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1515","86618","BK1247","LU0051755006.USD","06618","BK1591","SGXZ62798434.SGD","BK1142","BK1571","09939","BK1574","LU0456827905.SGD","BK1615","BK1589","SGXZ86797644.SGD"],"gpt_icon":0},{"id":"2608580600","title":"丹诺医药递表港交所；碧桂园称2025年完成房屋交付近17万套丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2608580600","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608580600?lang=zh_cn&edition=full","pubTime":"2026-02-04 01:12","pubTimestamp":1770138769,"startTime":"0","endTime":"0","summary":"｜2026年2月4日星期三｜NO.1东鹏饮料正式登陆港交所2月3日，东鹏饮料（HK09980，SH605499）正式登陆港交所主板。截至当日收盘，其港股报251.80港元/股，微涨1.53%，总市值1412亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602043640490921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043640490921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1507","BK1521","BK1574","BK1515","BK1610","02007","BK1240","BK1589","BK1555","BK1161","09939"],"gpt_icon":0},{"id":"2608808987","title":"【新股IPO】丹诺医药（苏州）股份有限公司 - B向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2608808987","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608808987?lang=zh_cn&edition=full","pubTime":"2026-02-03 23:24","pubTimestamp":1770132252,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所2月3日披露，丹诺医药 股份有限公司 - B向港交所主板提交上市申请，中信证券、农银国际为联席保荐人。公司核心产品利福特尼唑是自1982年发现幽门螺杆菌以来，全球首个且截至最后实际可行日期唯一治疗该细菌感染的新分子实体候选药物。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ZWZlYzkyOGQ5ZGUzNDkxY2I2NjIxYmMxZDI0OGZjOTU0MjU2ODIxNjg3.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWZlYzkyOGQ5ZGUzNDkxY2I2NjIxYmMxZDI0OGZjOTU0MjU2ODIxNjg3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974499","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1574","BK1161","BK1515","09939","HEXmain"],"gpt_icon":0},{"id":"2608389714","title":"瞄准过敏性鼻炎新药！济川药业“牵手”普祺医药，后者正冲刺港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2608389714","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608389714?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:09","pubTimestamp":1770127740,"startTime":"0","endTime":"0","summary":"　　济川药业将布局瞄准过敏性鼻炎新药。　　2月3日，济川药业发布公告称，公司全资子公司济川药业集团有限公司与北京普祺医药科技股份有限公司签署独家商业化合作协议，约定授权济川有限在合作期限内独家负责普祺医药拥有的普美昔替尼鼻喷雾剂在中国的商业化。　　值得一提的是，普美昔替尼的研发方普祺医药，目前正在冲刺港股IPO。这也意味着，此次商业授权将给普祺医药带来一笔不菲的收入。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-03/doc-inhkqfvf4193850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1161","BK0187","BK0239","BK1574","BK0077","BK1515","VXUS","BK0188","BK0201","BK4585","BK0028","VT","600566","BK0012","BK4588","09939"],"gpt_icon":0},{"id":"2608874712","title":"丹诺医药冲刺港股：9个月亏损1.15亿 估值20亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874712","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608874712?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:54","pubTimestamp":1770126850,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司（简称：“丹诺医药”）日前更新招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260203/6390575241379964971438826.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260203/6390575241379964971438826.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32563/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1161","BK1574","BK4585","VXUS","159938","VT","BK1515","09939","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0674},{"period":"1month","weight":0.2406},{"period":"3month","weight":0.538},{"period":"6month","weight":0.2705},{"period":"1year","weight":1.9551},{"period":"ytd","weight":0.3418}],"compareEarnings":[{"period":"1week","weight":-0.0302},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.2713},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.172028},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}